Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression

European Journal of Haematology

Volumn 73, Issue 1, 2004, Pages 36-42

  Molica, Stefano ^a,e   Vitelli, Gaetano ^b   Levato, Domenico ^a   Giannarelli, Diana ^b   Vacca, Angelo ^c   Cuneo, Antonio ^d   Ribatti, Domenico ^c   Digiesi, Giovanna ^b  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e NONE   (Italy)

Author keywords

Angiogenin; Disease progression; Stage A CLL

Indexed keywords

ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; LACTATE DEHYDROGENASE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; B CELL LEUKEMIA; BONE MARROW; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KARYOTYPE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANK SUM TEST; RISK ASSESSMENT; SURVIVAL RATE; TRISOMY 12;

ADP-RIBOSYL CYCLASE; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIGENS, CD; ANTIGENS, CD38; BONE MARROW; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; KARYOTYPING; LEUKEMIA, B-CELL, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; MICROCIRCULATION; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REFERENCE VALUES; RIBONUCLEASE, PANCREATIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3042615975     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00269.x     Document Type: Article

References (37)

1. RIBATTI D, VACCA A, DAMMACCO F, ENGLISH D. Angiogenesis and antiangiogenesis in hematological malignancies. J Hematother Stem Cell Res 2003;12:11-22.
2. AGUAYO A, KANTARJIAN H, MANSHOURI T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-2245.
3. KINI AR, KAY NE, PTERSON LC. Increased bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 2000;8:1414-1418.
4. MOLICA S, VACCA A, RIBATTI D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002;100:3344-3351.
5. MOLICA S, VITELLI G, LEVATO D, GANDOLFO GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;107:605-610.
6. MENZEL T, RAHMAN Z, CALLEJA E, et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996;87:1056-1063.
7. KONIG A, MENZEL T, LYNES S, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B-cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997, 11: 258-265.
8. VALLEE BL, RIORDAN JF. Organogenesis and angiogenin. Cell Moll Life Science 1997;53:803-815.
9. VERSTOVSEK S, KANTATJIAN H, AGUAYO A, et al. Significance of angiogenin plasma concentration in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 2001;114:290-295.
10. BRUNNER B, GUNSILIUS E, SCHUMACHER P, ZWIERZINA H, GASTI G, STAUDER R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplatic syndromes and acute myeloid leukemia. J Hematother Stem Cell Res 2002;11:119-125.
11. GLENJEN N, MOSEVOLL KA, BRUSERUD O. Serum levels of angiogenin, basic fibroblastic growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Cancer Diagn Ther 2002;4:86-94.
12. BINET JL, AUQUIER A, DIGHIERO G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-212.
13. CHESON BD, BENNETT JM, GREVER M, et al. National Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
14. RAI KR, SAWITSKY A, CRONKITE EP, CHANANA AD, LEVY NR, PASTERNACK BS. Clinical staging of chronic lymphocytic leukaemia. Blood 1975;46:219-234.
15. ROZMAN C, MONTSERRAT E, RODRIGUEZ-FERNANDEZ JM, et al. Bone marrow histologic pattern: the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984;64:642-653.
16. MONTSERRAT E, SANCHEZ-BISONO J, VINOLAS N, ROZMAN C. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. Br J Haematol 1986;62:567-578.
17. CUNEO A, BIGONI R, RIGOLIN GM, et al. Acquired deletion of the ataxia telengiactasia (ATM) locus in non-Hodgkin's lymphoma: correlation with clinicobiological features. J Clin Oncol 2000;18:2607-2614.
18. MOLICA S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991;78:895-899.
19. CHOPRA V, DINH TV, HANNIGAN EV. Angiogenin, interleukins, and growth factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. Cancer J Sc Am 1996;2:279-285.
20. CHOPRA V, DINH TV, HANNIGAN EV. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 1997;123:167-172.
21. WECHSEL HW, BICHLER KH, FEIL G, LOESER W, LAHME S, PETRI S. Renal cell carcinoma: relevance of angiogenic factors. Anticancer Res 1999;19:1537-1540.
22. LI D, BELL J, BROWN A, BERRY CL. The observation of angiogenin and basic fibroblastic growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomass, and hepatocellular carcinomas. J Pathol 1994;172:171-175.
23. HARTMANN A, KUNZ M, KOSTLIN S, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999;59:1578-1583.
24. RYBAK SM, FETT JW, YAO QZ, VALLEE BL. Angiogenin mRNA in human tumor and normal cells. Biochem Biophys Res Comm 1987;146:1240-1248.
25. MOENNER M, GUSSE M, HATZI E, BADET J. The widspread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur J Biochem 1994;226:483-490.
26. SHYMOYAMA S, GANSAUGE F, GANSAUGE F, NEGRI G, OOHARA T, BEGER HG. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 1996;56:2703-2706.
27. SHYMOYAMA S, YAMASAKI K, KAWAHARA M, KAMINISHI M. Increased angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin Cancer Res 1999;5:1125-1130.
28. MIYAKE H, HARA I, YAMANAKA K, GOHJI K, ARAKAWA S, KAMODONO S. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 1999;86:316-324.
29. OLSON KA, FRENCH TC, VALLEE BL, FETT JW. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res 1994;54:4576-4579.
30. STRYDOM DJ. The angiogenins. Cell Mol Life Sci 1998;54:811-824.
31. CHRISTIANSEN I, SUNDSTROM C, TOTTERMAN T. Elevated serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) closely reflec tumour burden in chronic B-lymphocytic leukaemia. Br J Haematol 1988;103: 1129-1137.
32. KOCH AE, HALLORAN MM, HASKELL CJ, SHAH MR, POLVERINI PJ. Angiogenesis mediated by by solubile forms of E-selectin and vascular cell adhesion molecole-1. Nature 1995;376:517-519.
33. CALIGARIS-CAPPIO F. Role of microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003;123:380-388.
34. MOLICA S. Prognostic factors in chronic lymphocytic leukemia. In: CHESON BD, ed. Chronic Lymphoid Leukemias, 2nd edn, Revised and Expanded. New York: Marcel Dekker, 2001:231-260.
35. RAI KR, CHIORAZZI N. Determing the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 2003;348:1797-1799.
36. CRESPO M, BOSCH F, VILLAMOR N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
37. DOHNER H, STILGENBAUER S, BRENNER A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.